Synthesis and Evaluation of BSA-Loaded PLGA-Chitosan Composite Nanoparticles for the Protein-Based Drug Delivery System

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Jun 5

PMID 37273604

Authors

Manish Gaur

Sarita Maurya

Mohd Sohail Akhtar

Awadh Bihari Yadav

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to synthesize composite nanoparticles (NPs) based on poly(d,l-lactic--glycolic acid) (PLGA) and chitosan (CS) and evaluate their suitability for the delivery of protein-based therapeutic molecules. Composite NPs possess a unique property which is not exhibited by any other polymer. Unlike other polymers, only the composite NPs lead to improved transfection efficiency and sustained release of protein. The composite NP were prepared by grafting CS on the surface of PLGA NPs through EDC-NHS coupling reaction. The size of bovine serum albumin (BSA)-loaded PLGA NPs and BSA-loaded PLGA-CS composite NPs was 288 ± 3 and 363 ± 4 nm, respectively. The zeta potential of PLGA NPs is -18 ± 0.23, and that of composite particles is 19 ± 0.40, thus confirming the successful addition of CS on the surface of PLGA NPs. Composite NPs were characterized using dynamic light scattering, scanning/transmission electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, release profile, and gel electrophoresis. The encapsulation efficiency of PLGA NPs was 88%. These composite NPs were easily uptaken by the A549 cell line with no or minimal cytotoxicity. The present study emphasizes that the composite NPs are suitable for delivery of BSA into the cells with no cytotoxicity or very little cytotoxicity, while maintaining the integrity of the encapsulated BSA.

Citing Articles

Nanoparticle containing recombinant excretory/secretory-24 protein of enhanced the cellular immune responses in mice.

Hasan M, Haseeb M, Gadahi J, Ehsan M, Wang Q, Lakho S Front Vet Sci. 2024; 11:1470084.

PMID: 39600880 PMC: 11588750. DOI: 10.3389/fvets.2024.1470084.

Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study.

Husseini R, Ibrahim T, Hamed E, Gomaa E, Faisal M, Wan G Pharmaceutics. 2024; 16(11).

PMID: 39598487 PMC: 11597075. DOI: 10.3390/pharmaceutics16111364.

Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article.

Fasquelle F, Scuotto A, Howsam M, Betbeder D Pharmaceutics. 2024; 16(2).

PMID: 38399301 PMC: 10892173. DOI: 10.3390/pharmaceutics16020247.

Uptake Quantification of Antigen Carried by Nanoparticles and Its Impact on Carrier Adjuvanticity Evaluation.

Zhu Y, Cui M, Liu Y, Ma Z, Xi J, Tian Y Vaccines (Basel). 2024; 12(1).

PMID: 38250841 PMC: 10818693. DOI: 10.3390/vaccines12010028.

References

Jin M, Seo S, Kim B, Hwang S, Kang Y, Shin J . Combined Application of Prototype Ultrasound and BSA-Loaded PLGA Particles for Protein Delivery. Pharm Res. 2021; 38(8):1455-1466. DOI: 10.1007/s11095-021-03091-z. View

Muralidharan P, Malapit M, Mallory E, Hayes Jr D, Mansour H . Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015; 11(5):1189-99. DOI: 10.1016/j.nano.2015.01.007. View

Yu Z, Yu M, Zhang Z, Hong G, Xiong Q . Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear. Nanoscale Res Lett. 2014; 9(1):343. PMC: 4106659. DOI: 10.1186/1556-276X-9-343. View

Kashyap S, Singh A, Mishra A, Singh V . Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles. Res Pharm Sci. 2019; 14(2):93-106. PMC: 6791168. DOI: 10.4103/1735-5362.253356. View

Yadav A, Mishra P, Mishra A, Mishra P, Jain S, Agrawal G . Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine. 2007; 3(4):246-57. DOI: 10.1016/j.nano.2007.09.004. View

Devulapally R, Paulmurugan R . Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 6(1):40-60. PMC: 3865230. DOI: 10.1002/wnan.1242. View

Ali A, Ahmed S . A review on chitosan and its nanocomposites in drug delivery. Int J Biol Macromol. 2017; 109:273-286. DOI: 10.1016/j.ijbiomac.2017.12.078. View

Elbatanony R, Parvathaneni V, Kulkarni N, Shukla S, Chauhan G, Kunda N . Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. Drug Deliv Transl Res. 2020; 11(3):927-943. PMC: 7738377. DOI: 10.1007/s13346-020-00802-8. View

Wang Y, Li P, Kong L . Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 2013; 14(2):585-92. PMC: 3665987. DOI: 10.1208/s12249-013-9943-3. View

10.

Ha H, Kim J, Lee M, Jun W, Lee W . Cellular Uptake and Cytotoxicity of β-Lactoglobulin Nanoparticles: The Effects of Particle Size and Surface Charge. Asian-Australas J Anim Sci. 2015; 28(3):420-7. PMC: 4341088. DOI: 10.5713/ajas.14.0761. View

11.

Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y . Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009; 382(1-2):198-204. DOI: 10.1016/j.ijpharm.2009.07.023. View

12.

De Negri Atanasio G, Ferrari P, Campardelli R, Perego P, Palombo D . Poly (Lactic--Glycolic Acid) Nanoparticles and Nanoliposomes for Protein Delivery in Targeted Therapy: A Comparative Study. Polymers (Basel). 2020; 12(11). PMC: 7692461. DOI: 10.3390/polym12112566. View

13.

Vaidya B, Kulkarni N, Shukla S, Parvathaneni V, Chauhan G, Damon J . Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. Int J Pharm. 2020; 577:118995. DOI: 10.1016/j.ijpharm.2019.118995. View

14.

Jennings J, Wells C, McGraw G, Velasquez Pulgarin D, Whitaker M, Pruitt R . Chitosan coatings to control release and target tissues for therapeutic delivery. Ther Deliv. 2015; 6(7):855-71. DOI: 10.4155/tde.15.31. View

15.

Nag S, Das Saha K . Chitosan-Decorated PLGA-NPs Loaded with Tannic Acid/Vitamin E Mitigate Colon Cancer via the NF-κB/β-Cat/EMT Pathway. ACS Omega. 2021; 6(43):28752-28769. PMC: 8567364. DOI: 10.1021/acsomega.1c03477. View

16.

Arafa M, Mousa H, Afifi N . Preparation of PLGA-chitosan based nanocarriers for enhancing antibacterial effect of ciprofloxacin in root canal infection. Drug Deliv. 2019; 27(1):26-39. PMC: 6968620. DOI: 10.1080/10717544.2019.1701140. View

17.

Hajavi J, Ebrahimian M, Sankian M, Khakzad M, Hashemi M . Optimization of PLGA formulation containing protein or peptide-based antigen: Recent advances. J Biomed Mater Res A. 2018; 106(9):2540-2551. DOI: 10.1002/jbm.a.36423. View

18.

Kang B, Choi J, Lee S, Lee J, Kim T, Jang W . Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. Carbohydr Polym. 2017; 159:39-47. DOI: 10.1016/j.carbpol.2016.12.009. View

19.

Agarwal S, Mohamed M, Mizuki T, Maekawa T, Kumar D . Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy. J Mater Chem B. 2019; 7(39):5896-5919. DOI: 10.1039/c9tb01131e. View

20.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A . Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2). PMC: 6027495. DOI: 10.3390/pharmaceutics10020057. View